DK1154792T3 - Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans - Google Patents

Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans

Info

Publication number
DK1154792T3
DK1154792T3 DK00906305T DK00906305T DK1154792T3 DK 1154792 T3 DK1154792 T3 DK 1154792T3 DK 00906305 T DK00906305 T DK 00906305T DK 00906305 T DK00906305 T DK 00906305T DK 1154792 T3 DK1154792 T3 DK 1154792T3
Authority
DK
Denmark
Prior art keywords
sub
adjuvant
fatty acids
monoglycerides
vaccine formulation
Prior art date
Application number
DK00906305T
Other languages
Danish (da)
English (en)
Inventor
Ulf Schroeder
Stefan Svenson
Original Assignee
Eurocine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocine Ab filed Critical Eurocine Ab
Application granted granted Critical
Publication of DK1154792T3 publication Critical patent/DK1154792T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00906305T 1999-02-12 2000-02-09 Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans DK1154792T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9900495A SE9900495D0 (sv) 1999-02-12 1999-02-12 Vaccine composition
PCT/EP2000/001046 WO2000047225A2 (fr) 1999-02-12 2000-02-09 Composition de vaccin

Publications (1)

Publication Number Publication Date
DK1154792T3 true DK1154792T3 (da) 2007-02-12

Family

ID=20414469

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00906305T DK1154792T3 (da) 1999-02-12 2000-02-09 Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans

Country Status (10)

Country Link
US (1) US6936260B1 (fr)
EP (1) EP1154792B1 (fr)
AT (1) ATE342065T1 (fr)
AU (1) AU769390B2 (fr)
DE (1) DE60031243T2 (fr)
DK (1) DK1154792T3 (fr)
ES (1) ES2275495T3 (fr)
NZ (1) NZ513130A (fr)
SE (1) SE9900495D0 (fr)
WO (1) WO2000047225A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR030800A0 (en) * 2000-09-22 2000-10-12 Pharmalink International Limited Immunomodulatory preparation
CN1612753A (zh) * 2001-11-14 2005-05-04 诺瓦瓦克斯有限公司 分枝杆菌疫苗
PT1461054E (pt) * 2001-12-11 2010-08-09 Pasteur Institut Preparações de bactérias gram positivas para o tratamento de doenças que implicam uma desregulação imunitária
CU23476A1 (es) * 2004-01-29 2009-12-17 Ct Ingenieria Genetica Biotech Formulación adyuvante conteniendo una emulsión oleosa con aceite de jojoba
EP1843787B1 (fr) * 2005-01-28 2011-11-02 North-West University Combinaison de lipides et d'oxyde nitreux comme adjuvant pour renforcer l'efficacité de vaccins
DK2144626T3 (en) 2007-04-12 2015-02-09 Mico Bio Inc Tuberculosis vaccine and method of using same
CN102441162B (zh) * 2010-10-04 2018-07-24 免疫产品美国股份有限公司 结核病的治疗和预防
WO2012145491A2 (fr) * 2011-04-20 2012-10-26 Jason Fisher Composition et procédé pour augmenter une réponse immunitaire
EP2620159A1 (fr) * 2012-01-24 2013-07-31 Institut Pasteur Traitement du cancer amélioré par immunothérapie par BCG ou des mycobactéries non pathogènes apparentées du point de vue des antigènes
WO2018006939A1 (fr) 2016-07-05 2018-01-11 Universidad De Zaragoza Vaccin inactivé contre la tuberculose.
WO2020115161A1 (fr) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant destiné à être utilisé contre des pathogènes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) * 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
WO1993006921A1 (fr) 1991-10-04 1993-04-15 Gs Biochem Ab Particules, procede de preparation desdites particules et utilisations
DK17093D0 (da) 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
ATE318147T1 (de) * 1996-03-25 2006-03-15 Medarex Inc Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering

Also Published As

Publication number Publication date
ATE342065T1 (de) 2006-11-15
ES2275495T3 (es) 2007-06-16
NZ513130A (en) 2003-01-31
AU2803500A (en) 2000-08-29
DE60031243D1 (de) 2006-11-23
DE60031243T2 (de) 2007-05-24
SE9900495D0 (sv) 1999-02-12
US6936260B1 (en) 2005-08-30
AU769390B2 (en) 2004-01-22
EP1154792B1 (fr) 2006-10-11
WO2000047225A2 (fr) 2000-08-17
EP1154792A2 (fr) 2001-11-21
WO2000047225A3 (fr) 2000-12-14

Similar Documents

Publication Publication Date Title
DK0777490T3 (da) Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans
NO20002741L (no) Vaksine-blandinger omfattende kitosan, for mukosal administrasjon
DK1154792T3 (da) Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans
MD1586G2 (ro) Inducere a unui răspuns citotoxic T-limfocitar
NO20052010L (no) Immunogen sammensetning
EP1955709A3 (fr) Compositions d'adjuvant d'amélioration des réponses immunitaires aux vaccins à base de polynucléotide
NO976060L (no) Vaksiner mot hepatitt C
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
BRPI0000126B8 (pt) composição de vacina, composição adjuvante e método de produção de uma composição de vacina
EP2275121A3 (fr) Vaccins contre le streptococcus pneumoniae à base de protéine
CA2258217A1 (fr) Composes cyclopentane substitues convenant comme inhibiteurs des neuraminidases
ATE284710T1 (de) Adjuvans für vitale impfstoffe
DK0745388T3 (da) Mammalt vaccinepræparat omfattende squalen eller squalan, phospholipid og et overfladeaktivt stof som adjuvans
GB9306731D0 (en) Vaccines
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
SE9602280D0 (sv) Immunstimulerande lipidformulering
DK1150713T3 (da) Vaccineformulering der omfatter monoglycerider eller fedtsyrer som adjuvans
IL116010A0 (en) Immunogenic compositions
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
BR9713296A (pt) Processo para a preparação de derivados 2-amino-2-imidazolino, guanidino, e 2-amino-3,4,5,6-tetrahidro-pirimidina
ES2136965T3 (es) Derivados de 17-hidroxiiminoalquil y 17-hidroxiiminometilalquenil ciclopentanperhidrofenantreno activos sobre el sistema cardiovascular un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
KR910002455A (ko) 아크릴산 유도체를 함유하는 제약 조성물 및 의약으로서 이들의 사용
ITTO20001044A0 (it) Procedimento e impianto per il trattamento di prodotti di uovo e simili, destinati all'uso alimentare.
KR890701118A (ko) 혈소판 감소증 예방 및 치료제
SU1615917A1 (ru) Адъювант